As an economic and financial center, Shanghai has outstanding advantages in integrated circuits, biomedicine and new materials. The introduction of this merger and reorganization plan highlights Shanghai's determination to actively develop new quality productive forces and achieve autonomy and control.The benefits are endless.Analysts said that the plan is expected to benefit Shanghai local stocks from multiple dimensions.
[The time is ripe for Shanghai stocks to become monsters in batches! 】Many stocks have doubled.
Shanghai state-owned shares have these.As an economic and financial center, Shanghai has outstanding advantages in integrated circuits, biomedicine and new materials. The introduction of this merger and reorganization plan highlights Shanghai's determination to actively develop new quality productive forces and achieve autonomy and control.The stagflation stocks mainly include Haohaishengke, Shanghai Laishi and Weir. Among them, Haohai Shengke increased by less than 10%. The company is a scientific and technological innovative enterprise that applies biomedical materials technology and genetic engineering technology to research, develop, produce and sell medical devices and drugs. It is committed to providing innovative medical products for the market through technological innovation and transformation, integration of domestic and foreign resources and large-scale production, and gradually realizing the import substitution of related medical products, thus becoming a leading enterprise in the field of biomedical materials.
Strategy guide 12-14
Strategy guide 12-14
Strategy guide
Strategy guide 12-14
Strategy guide 12-14
Strategy guide 12-14